Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
Join this webinar to hear about the latest RMM technology and how it aligns with UPS testing criteria.
news

Kadcyla new deal means NICE positive recommendation in draft guidance

A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.

NHS England and the drug’s manufacturer, Roche, have agreed to a new commercial access arrangement for the NHS. This means that NICE can now recommended the drug as cost effective for routine use on the NHS.

Trastuzumab emtansine (also called Kadcyla) is currently being funded through the Cancer Drugs Fund (CDF). If there are no appeals against the new draft guidance, the drug will move out of the CDF into routine NHS funding later this summer.

Around 1200 people with HER2-positive, unresectable, metastatic breast cancer would then be eligible to receive trastuzumab emtansine.

Cost of drug

Trastuzumab emtansine (Kadcyla), which costs around £90,000 per patient at its full list price, is licensed to treat HER2-positive breast cancer which has spread to other parts of the body, cannot be surgically removed and has stopped responding to initial treatment.

The committee considered a new cost-effectiveness analysis that used a revised confidential commercial access agreement.

Comparable treatment

Another key factor in the decision was the committee’s agreement, following comments received during consultation on the previous draft guidance, that it was appropriate to compare trastuzumab emtansine (Kadcyla) with trastuzumab plus capecitabine because this is now considered standard treatment for people with advanced breast cancer.

Based on the clinical and cost effectiveness analysis, using this comparator, incorporating the revised commercial access agreement and applying end-of-life criteria, the drug now comes within the range considered to be a cost-effective use of NHS resources.

Petition

Professor Carole Longson MBE, director of the centre for health technology evaluation at NICE, said: “The committee acknowledged the comments received from patients during the consultation on the draft recommendations for trastuzumab emtansine (Kadcyla), in particular that 115,000 people had signed a Breast Cancer Now petition urging NICE and the company to ensure that it remains available.

“We are therefore very pleased that the company and NHS England have been able to agree a deal that will achieve this. Since we started reassessing the drugs available through the Cancer Drugs Fund, companies have responded positively and shown that they can offer good deals when it comes to pricing. This has meant that we have been able to recommend these drugs for routine funding, which is clearly very good news for both patients and the NHS.”